• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, March 29

Aurobindo Pharma Ltd (APL) has announced that it has received final approval of the United States Food and Drug Administration (USFDA) for Zidovudine capsules 100 mg.

Zidovudine is in the class of drugs called nucleoside reverse transcriptase inhibitors (NRTIs) that help keep the AIDS virus from reproducing. It is intended to use with other antiretroviral agents for the treatment of HIV-1 infection.

In a press release here on Wednesday, the company said the approval would pave way for it to market Zidovudine in the US market and also qualify under the President's Emergency Plan for AIDS Relief (PEPFAR) programme. Further, the company said the approval is in addition to having final approval for Zidovudine tablets and oral solutions.

More Stories on : Regulatory Bodies & Rulings | Health | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Opto Circuits fixes offer price at Rs 240-270

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line